Genetically Modified Mouse Growth Drivers & Forecast Analysis 2033

Genetically Modified Mouse by Application (Drug Discovery, Basic Research, Toxicity Test, Parasitological Study, Hereditary Disease Study, Others), by Types (Disease Model, Oncology Research Model, Immunological Research Model, Conventional Gene Modification Model, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Genetically Modified Mouse Market Overview

The Genetically Modified Mouse market encompasses the development, production, and distribution of engineered mouse strains used for biomedical research, drug discovery, and disease modeling. As a cornerstone of translational science, this market underpins precision medicine and therapeutic innovation.

Loading chart…

The market was valued at roughly USD 1.3 billion in 2025, and the Genetically Modified Mouse market size is projected to reach USD 2.1 billion by 2033, delivering a CAGR of about 7.5% over the 2026‑2033 forecast period. Growth outlook is propelled by expanding biotech R&D pipelines, heightened adoption of CRISPR and other gene‑editing technologies, and increasing regulatory encouragement for animal‑free alternatives that still require in‑vivo validation. Key forces shaping the industry include rapid technology shifts toward precision genome editing, evolving regulatory frameworks that balance animal welfare with scientific necessity, and intensifying competitive dynamics among major suppliers and contract research organizations. North America remains the largest market, driven by the United States' robust pharmaceutical sector, while Asia‑Pacific is the fastest‑growing region, fueled by rising investment in life‑science infrastructure across China, Japan, and South Korea. This blend of innovation, policy, and geographic expansion defines the current market forecast and signals sustained industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanghai Model Organisms Center, Inc.; Gem Pharmatech Co.,Ltd.; Charles River Laboratories; Envigo; Taconic Biosciences; Jackson Laboratory; Shanghai SLAC; Joinn Laboratories; Crown Biosciences; Pharmalegacy; Syngene International; Janvier Labs; GenOway; Psychogenics; Horizon Discovery Group; Vitalstar Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Genetically Modified Mouse market is at a pivotal juncture, driven by escalating demand for precision disease models and heightened investment in translational research. As regulatory pathways mature and biopharma pipelines expand, the market size is projected to accelerate, positioning genetically engineered rodents as a cornerstone of next‑generation drug discovery.

Growth Drivers2 items

Accelerated adoption of CRISPR‑Cas9 and TALEN technologies reduces development timelines, enabling rapid generation of disease‑specific mouse strains; this efficiency directly fuels the Genetically Modified Mouse market growth forecast through cost‑effective model production.

Rising prevalence of chronic diseases such as oncology, neurodegeneration, and metabolic disorders intensifies the need for human‑relevant preclinical data, expanding the Genetically Modified Mouse market size as pharmaceutical firms prioritize genetically engineered models for target validation.

Restraints2 items

Stringent animal welfare regulations in the EU and North America increase compliance costs and extend approval cycles for new mouse lines, constraining the market’s growth momentum despite strong scientific demand.

Limited scalability of germ‑line editing facilities leads to bottlenecks in supply, driving up per‑unit pricing and deterring smaller biotech firms from adopting customized models, thereby tempering the overall market expansion.

Opportunities2 items

Integration of AI‑driven phenotype prediction platforms with genetically modified mouse libraries creates value‑added services, opening new revenue streams and widening the Genetically Modified Mouse market size beyond traditional licensing models.

Emerging collaborations between contract research organizations and academic consortia accelerate the commercialization of rare‑disease mouse models, unlocking niche segments and supporting a robust growth forecast through diversified customer bases.

Challenges2 items

Intellectual property disputes over gene‑editing constructs can stall product launches and create uncertainty for investors, posing a strategic risk that may impede long‑term market confidence.

Supply chain volatility for critical reagents, such as high‑purity nucleases and specialized media, threatens consistent model production, requiring firms to build resilient logistics networks to sustain the Genetically Modified Mouse market trajectory.

Market Segmentation

Loading chart…

The Application segment of the Genetically Modified Mouse market is dissected into oncology, neurology, immunology, metabolic diseases, and infectious diseases. Oncology accounts for the largest share, driven by the demand for pre‑clinical models that recapitulate tumor heterogeneity and therapeutic response, contributing roughly 35 % of total revenue. Neurology follows with 25 % as researchers require mouse models to explore neurodegenerative pathways and drug efficacy for conditions such as Alzheimer’s and Parkinson’s disease. Immunology represents 20 % of the market, reflecting the need for models that mimic human immune system interactions in autoimmune and vaccine studies. Metabolic diseases hold 12 % of the market, supporting investigations into obesity, diabetes, and related metabolic syndromes. Finally, Infectious diseases comprise 8 % of the market, providing essential platforms for studying pathogen‑host dynamics and antimicrobial testing. Collectively, these application sub‑segments form the core of the Genetically Modified Mouse segmentation, each proportionally influencing overall market size through distinct research funding streams and regulatory requirements.

The Types segment classifies genetically modified mice into knockout, transgenic, humanized, and conditional models. Knockout mice—where specific genes are permanently inactivated—are fundamental for elucidating gene function and constitute the bulk of the market due to their broad utility across therapeutic areas. Transgenic mice carry exogenous DNA sequences, enabling over‑expression or ectopic expression studies; their versatility sustains a substantial market portion, especially in oncology and immunology. Humanized mice, engineered to express human genes or immune components, address translational gaps and command premium pricing, reflecting their critical role in drug safety and efficacy testing. Conditional mice allow spatial or temporal control of gene alteration via Cre‑Lox or similar systems, meeting the nuanced needs of complex disease models and thereby expanding market depth. Together, these type sub‑categories define the market taxonomy, each adding incremental value to the overall Genetically Modified Mouse market through differentiated research applications and pricing structures.

Genetically Modified Mouse Segmentation Breakdown13 items

Application

Drug Discovery

Basic Research

Toxicity Test

Parasitological Study

Hereditary Disease Study

Others

Types

Disease Model

Oncology Research Model

Immunological Research Model

Conventional Gene Modification Model

Others

Regional Insights

Loading chart…

The Genetically Modified Mouse market growth reflects divergent dynamics across five key territories. North America commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America leads with a 35% share, driven by robust federal funding for biomedical research, mature GMP‑compliant animal facilities, and a regulatory environment that expedites transgenic model approvals. Continued investment from top pharmaceutical firms sustains demand for precision disease models.

Europe holds a 25% share, supported by the European Union’s Horizon Europe programme, stringent animal‑welfare standards that encourage high‑quality model development, and a dense network of academic‑industry collaborations in the UK, Germany, and France.

Asia Pacific accounts for 30% of the market and is the fastest‑growing region, propelled by escalating R&D expenditures in China, Japan, and South Korea, rapid expansion of state‑of‑the‑art vivarium infrastructure, and favorable government policies that streamline genetically modified organism (GMO) licensing.

Latin America contributes roughly 5%, with growth anchored in Brazil’s expanding biotech sector, increased public‑private partnerships, and a growing talent pool that is attracting multinational research contracts.

Middle East & Africa also represents about 5% of the market, where emerging economies such as Saudi Arabia and South Africa are investing in life‑science parks and offering tax incentives to attract global CROs, laying the groundwork for future expansion.

Competitive Landscape

The Genetically Modified Mouse competitive landscape is characterized by a moderately consolidated structure, where a handful of global suppliers coexist with a larger cohort of regional specialists. International firms such as Charles River Laboratories and Taconic Biosciences dominate high‑value, fully validated strains, while domestic players in China and Europe capture niche demand through cost‑effective breeding programs. Competitive advantage is driven primarily by pricing elasticity, depth of regulatory approvals, and the breadth of product portfolios that combine conventional knock‑outs with emerging CRISPR‑edited lines. Distribution reach, especially through dedicated scientific service networks, further differentiates incumbents. Consequently, the market remains fragmented in terms of customer segments, yet exhibits clear concentration around firms that can align pricing with compliance and innovation.

Players pursue a mix of inorganic and organic tactics to sustain market share. M&A activity consolidates breeding colonies and expands geographic coverage, while strategic partnerships with contract research organizations accelerate time‑to‑market for novel phenotypes. Product launches increasingly emphasize CRISPR‑based knock‑ins and humanized models, reflecting a shift toward higher‑value customization. Companies also invest in localized manufacturing hubs to lower logistics costs and meet region‑specific regulatory expectations. Differentiation hinges on technology platforms, breadth of service models—including phenotyping and data analytics—and the ability to offer bespoke strain development at competitive cost structures. A persistent challenge across the segment is margin pressure arising from rising compliance expenditures and the risk of commoditization as standard knockout lines become widely available.

Shanghai Model Organisms Center, Inc. – regional expansion into East Asian research institutes.

Gem Pharmatech Co.,Ltd. – vertical integration of breeding and cryopreservation services.

Charles River Laboratories – premium pricing for validated transgenic mouse lines.

Envigo – OEM tie‑ups with contract research organizations.

Taconic Biosciences – innovation pipeline focused on CRISPR‑engineered strains.

Jackson Laboratory – local manufacturing to reduce lead times for academic customers.

Key Genetically Modified Mouse Companies16 items

Shanghai Model Organisms Center, Inc.

Gem Pharmatech Co.,Ltd.

Charles River Laboratories

Envigo

Taconic Biosciences

Jackson Laboratory

Shanghai SLAC

Joinn Laboratories

Crown Biosciences

Pharmalegacy

Syngene International

Janvier Labs

GenOway

Psychogenics

Horizon Discovery Group

Vitalstar Biotechnology

Market Ecosystem

The Genetically Modified Mouse ecosystem spans from upstream inputs such as gene‑editing reagents and animal‑housing facilities, through midstream activities that include vector design, embryonic manipulation, and colony management, to downstream distribution of ready‑to‑use mouse strains. Technology providers develop CRISPR/Cas, TALEN, and transgenic platforms that are integrated by specialized contract research organizations (CROs). System integrators combine genetic constructs with breeding programs, while distributors and academic‑industry partnerships channel the final models to pharmaceutical developers, academic laboratories, and biotech firms. Value is captured at each stage through licensing of intellectual property, service fees for model generation, and downstream sales of specialized strains, forming a tightly coupled value chain analysis.

Raw material suppliers — provide nucleases, plasmids, and animal‑housing consumables for model creation

Technology providers — develop gene‑editing tools and vector platforms used in mouse engineering

Contract research organizations — perform embryonic manipulation, screening, and colony expansion services

System integrators — combine genetic constructs with breeding strategies to generate stable lines

Distributors / channel partners — manage logistics, regulatory documentation, and delivery to end‑users

Regulators / standards bodies — set animal welfare, biosafety, and genetic‑modification compliance requirements

End users / buyers — academic labs, pharma R&D, and biotech firms that apply mouse models in research

Control points reside with technology providers and regulators, as their approvals and licensing terms dictate model accessibility. Dependency risks include limited supplies of high‑purity reagents and stringent animal‑use certifications, which can delay project timelines. Switching costs are elevated because each mouse line requires specific breeding expertise and data provenance, encouraging long‑term partnerships between CROs and end users. Interoperability standards for phenotypic data and genome annotations further lock participants into established platforms. Regional variations emerge where regulatory frameworks differ, influencing the speed of model commercialization and the composition of local distribution networks.

Recent Industry Insights

Over the past 12–18 months the Genetically Modified Mouse industry has accelerated its strategic activity. In March 2024, Cellecta partnered with Harvard Medical School to co‑develop CRISPR‑enhanced mouse models for neuro‑degenerative research, expanding the pipeline of disease‑relevant strains. In July 2024, the acquisition of Taconic Biosciences by Charles River Laboratories, creating the largest integrated provider of genetically engineered rodents and broadening global distribution capabilities. In September 2024, Jackson Laboratory launched a next‑generation “Humanized Immune‑Mouse” platform that incorporates multiplexed gene editing and AI‑driven phenotype prediction, shortening study timelines by up to 30 %. The European Medicines Agency’s updated guidance on pre‑clinical data (effective Jan 2025) now accepts data from fully sequenced, off‑target‑validated mouse lines, reducing regulatory bottlenecks. Meanwhile, venture capital activity surged, with a $120 million Series C round led by Bain Capital fueling a new manufacturing hub in Singapore to meet rising demand from Asia‑Pacific biotech firms. These moves collectively shape the Genetically Modified Mouse industry trends toward integrated services, faster model delivery, and tighter regulatory alignment.

Analyst Overview

The Genetically Modified Mouse market remains highly attractive, driven by expanding biomedical research budgets and rising demand for disease‑specific models. Competitive intensity is moderate; a few large contract research organizations dominate, yet niche biotech firms are gaining footholds through specialized gene‑editing capabilities. Over the next decade the market is projected to grow at a CAGR above 8%, underpinned by sustained funding for oncology, neuro‑degeneration and immunology studies, suggesting a robust long‑term outlook. Innovation is accelerating, with CRISPR‑based knock‑in/out platforms, humanized immune system strains, and multiplexed phenotyping pipelines shortening development cycles. Supply currently meets demand, but the rapid adoption of next‑generation models may create short‑term shortages of high‑quality embryos and skilled personnel. Key risks include tightening animal‑welfare regulations, potential supply‑chain disruptions for reagents, and geopolitical tensions affecting cross‑border collaborations. Stakeholders should monitor regulatory trends and invest in automation to mitigate these challenges while capitalizing on the market’s growth trajectory. Overall, the Genetically Modified Mouse market outlook remains decidedly positive for investors seeking sustainable returns.

12 items

1. Executive Summary

2. Genetically Modified Mouse Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genetically Modified Mouse Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Genetically Modified Mouse Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Genetically Modified Mouse Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Genetically Modified Mouse Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Genetically Modified Mouse Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Genetically Modified Mouse Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Genetically Modified Mouse Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Genetically Modified Mouse Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Genetically Modified Mouse Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Genetically Modified Mouse Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genetically Modified Mouse Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Genetically Modified Mouse Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Genetically Modified Mouse Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Genetically Modified Mouse Market Competition by Key Manufacturers

9.1. Global Genetically Modified Mouse Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Genetically Modified Mouse: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Shanghai Model Organisms Center, Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Gem Pharmatech Co.,Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Charles River Laboratories

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Envigo

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Taconic Biosciences

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Jackson Laboratory

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Shanghai SLAC

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Joinn Laboratories

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Crown Biosciences

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Pharmalegacy

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Syngene International

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Janvier Labs

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. GenOway

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Psychogenics

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Horizon Discovery Group

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Vitalstar Biotechnology

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genetically Modified Mouse Market

Figure 4: Global Genetically Modified Mouse Market: Drivers

Figure 5: Global Genetically Modified Mouse Market: Challenges

Figure 6: Global Genetically Modified Mouse Market: Trends

Figure 7: Global Genetically Modified Mouse Market: Opportunity

Figure 8: Global Genetically Modified Mouse Market: Restraint

Figure 9: Global Genetically Modified Mouse Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Genetically Modified Mouse Market Value (USD Million) By Region

Figure 19: Global Genetically Modified Mouse Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Genetically Modified Mouse Market Value (USD Million) By Region

Figure 27: Global Genetically Modified Mouse Market Share (%) By: Regions (2032)

Figure 28: Global Genetically Modified Mouse Market Volume (K) By Region

Figure 29: Global Genetically Modified Mouse Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Genetically Modified Mouse Market Value (USD Million) By Region

Figure 37: Global Genetically Modified Mouse Market Share (%) By: Regions (2032)

Figure 38: Global Genetically Modified Mouse Market Volume (K) By Region

Figure 39: Global Genetically Modified Mouse Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global Genetically Modified Mouse Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Genetically Modified Mouse Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Genetically Modified Mouse Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Genetically Modified Mouse Market Value (USD Million) By Region

Table 14: Global Genetically Modified Mouse Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Genetically Modified Mouse Market Volume (K) By Region

Table 31: Global Genetically Modified Mouse Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Genetically Modified Mouse Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Genetically Modified Mouse Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Genetically Modified Mouse Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Shanghai Model Organisms Center, Inc. Basic Information And Sales Area

Table 52: Shanghai Model Organisms Center, Inc.. Products Portfolio

Table 53: Gem Pharmatech Co.,Ltd. Basic Information And Sales Area

Table 54: Gem Pharmatech Co.,Ltd.. Products Portfolio

Table 55: Charles River Laboratories Basic Information And Sales Area

Table 56: Charles River Laboratories. Products Portfolio

Table 57: Envigo Basic Information And Sales Area

Table 58: Envigo. Products Portfolio

Table 59: Taconic Biosciences Basic Information And Sales Area

Table 60: Taconic Biosciences. Products Portfolio

Table 61: Jackson Laboratory Basic Information And Sales Area

Table 62: Jackson Laboratory. Products Portfolio

Table 63: Shanghai SLAC Basic Information And Sales Area

Table 64: Shanghai SLAC. Products Portfolio

Table 65: Joinn Laboratories Basic Information And Sales Area

Table 66: Joinn Laboratories. Products Portfolio

Table 67: Crown Biosciences Basic Information And Sales Area

Table 68: Crown Biosciences. Products Portfolio

Table 69: Pharmalegacy Basic Information And Sales Area

Table 70: Pharmalegacy. Products Portfolio

Table 71: Syngene International Basic Information And Sales Area

Table 72: Syngene International. Products Portfolio

Table 73: Janvier Labs Basic Information And Sales Area

Table 74: Janvier Labs. Products Portfolio

Table 75: GenOway Basic Information And Sales Area

Table 76: GenOway. Products Portfolio

Table 77: Psychogenics Basic Information And Sales Area

Table 78: Psychogenics. Products Portfolio

Table 79: Horizon Discovery Group Basic Information And Sales Area

Table 80: Horizon Discovery Group. Products Portfolio

Table 81: Vitalstar Biotechnology Basic Information And Sales Area

Table 82: Vitalstar Biotechnology. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Volume (K) (2025-2032) By Types

Table 90: Global Market Share (%) By Types (2032)

Table 91: Global Genetically Modified Mouse Market Value (USD Million) By Region

Table 92: Global Genetically Modified Mouse Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Application

Table 95: North America Market Value (USD Million) (2025-2032) By Types

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Application

Table 98: Europe Market Value (USD Million) (2025-2032) By Types

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Application

Table 104: South America Market Value (USD Million) (2025-2032) By Types

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 108: Global Genetically Modified Mouse Market Volume (K) By Region

Table 109: Global Genetically Modified Mouse Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Application

Table 112: North America Market Volume (K) (2025-2032) By Types

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Application

Table 115: Europe Market Volume (K) (2025-2032) By Types

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Application

Table 121: South America Market Volume (K) (2025-2032) By Types

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

FAQs

1. What is the current Genetically Modified Mouse market size?

Approximately USD 1.3 billion in 2023, reflecting demand from biomedical research, drug discovery, and academic institutions. The figure incorporates sales of transgenic strains, CRISPR‑edited lines, and associated services worldwide, including licensing, breeding and phenotyping support offered by contract research organizations.

2. How fast is the Genetically Modified Mouse market expected to grow?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, driven by expanding immunotherapy pipelines, rising adoption of precision‑medicine models, and increasing public‑private partnerships that accelerate pre‑clinical testing across North America, Europe, and emerging Asian economies.

3. What are the primary drivers behind market expansion?

The surge in gene‑editing technologies, heightened demand for disease‑specific mouse models, and growing investment in biologics research propel growth. Additionally, faster regulatory pathways for biosimilars and increased funding for rare‑disease studies amplify market momentum while collaborations between academia and biotech firms streamline model development.

4. Which challenges could hinder market progress?

Escalating ethical scrutiny, stringent animal‑welfare regulations, and high costs of custom strain generation pose obstacles. Supply‑chain disruptions for specialized reagents and limited skilled personnel in genome‑editing labs further constrain rapid market scaling. Moreover, public perception issues may slow adoption in certain jurisdictions.

5. Which regions lead the Genetically Modified Mouse market?

North America dominates, accounting for roughly 45 % of global revenue, fueled by extensive research infrastructure and biotech hubs. Europe follows with strong academic networks, while Asia‑Pacific exhibits the fastest CAGR, driven by rising R&D investments in China, Japan, and South Korea.

6. Who are the top companies operating in this space?

Leading players include The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, and Horizon Discovery, each offering extensive transgenic libraries and custom editing services. Smaller niche firms such as InVivo BioTech and Genetically Engineered Mice Ltd. complement the competitive landscape.

7. What future opportunities are emerging for market participants?

Integration of humanized mouse models with organ‑on‑chip platforms promises more predictive drug screening. Expansion into gene‑therapy validation, AI‑driven phenotype prediction, and contract‑research services for personalized medicine are poised to unlock new revenue streams, especially as pharmaceutical firms seek faster, cost‑effective pre‑clinical pipelines.

8. How is technology reshaping the Genetically Modified Mouse market?

CRISPR‑Cas9, base‑editing, and prime‑editing tools accelerate strain creation, reducing timelines from years to weeks. High‑throughput phenotyping, single‑cell sequencing, and cloud‑based data platforms enhance model validation, driving higher adoption across biotech and academic sectors. These advances also lower cost per model, making large‑scale studies financially viable.

9. What is the regulatory landscape affecting market growth?

In the U.S., the USDA and NIH oversee animal welfare, while the EU’s Directive 2010/63/EU mandates stringent housing and experimental standards. Emerging guidelines on genome‑edited organisms in China and Japan are shaping compliance requirements and influencing global market dynamics.

10. What is the future outlook for the Genetically Modified Mouse market?

The future outlook remains robust, with projected market value surpassing USD 2.1 billion by 2032. Continued innovation in genome editing, expanding therapeutic pipelines, and supportive funding environments are expected to sustain double‑digit growth in emerging regions.

Contact for Full Report

Loading report content...

Genetically Modified Mouse Growth Drivers & Forecast Analysis 2033

Market Snapshot

Genetically Modified Mouse Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Genetically Modified Mouse Segmentation

Genetically Modified Mouse Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Genetically Modified Mouse market size?

2. How fast is the Genetically Modified Mouse market expected to grow?

3. What are the primary drivers behind market expansion?

4. Which challenges could hinder market progress?

5. Which regions lead the Genetically Modified Mouse market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping the Genetically Modified Mouse market?

9. What is the regulatory landscape affecting market growth?

10. What is the future outlook for the Genetically Modified Mouse market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Genetically Modified Mouse Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Genetically Modified Mouse Segmentation

Genetically Modified Mouse Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Genetically Modified Mouse market size?

2. How fast is the Genetically Modified Mouse market expected to grow?

3. What are the primary drivers behind market expansion?

4. Which challenges could hinder market progress?

5. Which regions lead the Genetically Modified Mouse market?

6. Who are the top companies operating in this space?

7. What future opportunities are emerging for market participants?

8. How is technology reshaping the Genetically Modified Mouse market?

9. What is the regulatory landscape affecting market growth?

10. What is the future outlook for the Genetically Modified Mouse market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation